Jacobs Levy Equity Management
RANI icon

Jacobs Levy Equity Management’s Rani Therapeutics RANI Stock Holding History

Jacobs Levy Equity Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-18,712
Closed -$179K – 1024
2022
Q3 		$179K Buy
+18,712
New +$198K ﹤0.01% 939

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
ASGS
Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TWA
TPB Wealth Advisors San Antonio, Texas $183M AUM 9.21% 1-Year Est. Return

Jacobs Levy Equity Management's RANI Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Rani Therapeutics (RANI) in Q4 2022, closing a stake of 18,712 shares — an estimated $179K sold.

Jacobs Levy Equity Management first reported a position in RANI in Q3 2022 and held it in 1 quarter. The position peaked at $179K in Q3 2022. 34 funds tracked by Wall St. Rank hold RANI as of Q4 2022.

  • Jacobs Levy Equity Management reported no remaining Rani Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 18,712 Rani Therapeutics shares in Q4 2022, an estimated $179K.
  • Jacobs Levy Equity Management first reported a position in Rani Therapeutics in Q3 2022 and held it in 1 quarter.
  • Jacobs Levy Equity Management's Rani Therapeutics position peaked at $179K in Q3 2022.
  • 34 funds tracked by Wall St. Rank held Rani Therapeutics as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.